MX2023010175A - Antagonistas de canales de calcio tipo t y usos de los mismos. - Google Patents

Antagonistas de canales de calcio tipo t y usos de los mismos.

Info

Publication number
MX2023010175A
MX2023010175A MX2023010175A MX2023010175A MX2023010175A MX 2023010175 A MX2023010175 A MX 2023010175A MX 2023010175 A MX2023010175 A MX 2023010175A MX 2023010175 A MX2023010175 A MX 2023010175A MX 2023010175 A MX2023010175 A MX 2023010175A
Authority
MX
Mexico
Prior art keywords
calcium channel
type calcium
channel antagonists
cell
miro1
Prior art date
Application number
MX2023010175A
Other languages
English (en)
Inventor
Robert Zahler
David Nguyen
Xinnan Wang
Roeland Vanhauwaert
Vinita Bharat
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2023010175A publication Critical patent/MX2023010175A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En la presente se describe un método para reducir el nivel de Miro1 en una célula, el método que comprende poner en contacto la célula con una cantidad efectiva de un antagonista del canal de calcio tipo T.
MX2023010175A 2021-03-04 2022-03-03 Antagonistas de canales de calcio tipo t y usos de los mismos. MX2023010175A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156806P 2021-03-04 2021-03-04
US202163228505P 2021-08-02 2021-08-02
PCT/US2022/018682 WO2022216386A2 (en) 2021-03-04 2022-03-03 T-type calcium channel antagonists and uses thereof

Publications (1)

Publication Number Publication Date
MX2023010175A true MX2023010175A (es) 2023-09-07

Family

ID=83545681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010175A MX2023010175A (es) 2021-03-04 2022-03-03 Antagonistas de canales de calcio tipo t y usos de los mismos.

Country Status (10)

Country Link
US (1) US20240190865A1 (es)
EP (1) EP4301759A2 (es)
JP (1) JP2024508903A (es)
KR (1) KR20230167035A (es)
AU (1) AU2022255225A1 (es)
BR (1) BR112023016601A2 (es)
CA (1) CA3208202A1 (es)
IL (1) IL305381A (es)
MX (1) MX2023010175A (es)
WO (1) WO2022216386A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097632A1 (en) * 2022-10-31 2024-05-10 Acurex Biosciences Corporation Methods of reducing miro1 or phosphorylated alpha-synuclein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610701B2 (en) * 2001-02-09 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
JP5269761B2 (ja) * 2006-04-12 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション ピリジルアミドｔ型カルシウムチャンネルアンタゴニスト
KR20100072266A (ko) * 2007-10-24 2010-06-30 머크 샤프 앤드 돔 코포레이션 헤테로사이클 페닐 아미드 ｔ-형 칼슘 채널 길항제

Also Published As

Publication number Publication date
US20240190865A1 (en) 2024-06-13
CA3208202A1 (en) 2022-10-13
IL305381A (en) 2023-10-01
WO2022216386A9 (en) 2022-12-01
EP4301759A2 (en) 2024-01-10
WO2022216386A2 (en) 2022-10-13
JP2024508903A (ja) 2024-02-28
KR20230167035A (ko) 2023-12-07
BR112023016601A2 (pt) 2023-12-12
WO2022216386A3 (en) 2023-01-12
AU2022255225A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
ZA201705050B (en) Optimized solid substrates, tools for use with same and uses thereof for promoting cell and tissue growth
MX2022000088A (es) Rutina de inicio coordinada para dispositivos de control de una red.
MX2013005978A (es) Gel reticulado de poliamina y método de uso.
MX2020012086A (es) Método de transmisión de señales, estación base y nodo de red.
MX2023010175A (es) Antagonistas de canales de calcio tipo t y usos de los mismos.
MX2022001119A (es) Coordinacion de entrega y colocacion de concreto.
SG10201805426YA (en) Three-dimensional semiconductor device
BRPI0511870A (pt) programador de reuso restrito dinámico
MX2021012461A (es) Procesos para preparar y usar un secretoma derivado de células madre mesenquimales.
IN2014KN01169A (es)
PH12020551678A1 (en) Monoclonal antibody of nerve growth factor and encoding gene and use thereof
GB2568211A (en) A system and method for automatic identification and optimization of overshooting cells
BR112022002360A2 (pt) Método de comunicação sem fio e dispositivo terminal
IL260880B (en) Direct ammonia alkaline membrane fuel cell and method of operating same
MX2019001759A (es) Composicion de pretratamiento.
EP4175002A4 (en) ELECTROLYTIC ADDITIVE, BATTERY ELECTROLYTE COMPRISING IT AND SECONDARY BATTERY COMPRISING IT
HK1118568A1 (en) Copolymer of ethylene oxide or propylene oxide with an oxirane bearing an ionic group
WO2019204332A3 (en) Pak4 inhibitors and methods of use
EP4223872A3 (en) Methods for obtaining muscle derived cells
MX2017005077A (es) Gestion de reduccion de energia dinamica de dispositivos de red.
BR112021020255A2 (pt) Terminal de usuário e método de radiocomunicação
MX2019000989A (es) Metodo de fabricacion de tampon.
MX2021008305A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa.
EP4123250A4 (en) AUTOMATIC WATER SUPPLY DEVICE, REFRIGERATOR HAVING THE SAME AND AUTOMATIC WATER SUPPLY METHOD
WO2024081653A3 (en) Methods of lowering miro2 to treat neurodegenerative diseases